cirm future

Tracking the Wild CIRM: Sweeping Overviews of the Stem Cell/Gene Therapy Agency Are Upcoming

You can comment at the meetings or in writing ahead of the sessions

Dec 11 •

20th Anniversary of California's $12 Billion Stem Cell Program: Kudos and Criticism

CIRM launching new efforts to boost its impact, affordability of new therapies

Dec 5 •

CIRM's 'Daring,' $26 Million Bet on a Treatment for a Deadly Muscular Disease

Capricor and Cedars-Sinai researchers involved

Nov 5 •

California is Building a New Path to Rare Disease Cures; First Target is Neuro Afflictions

Fresh details unveiled last week by CIRM

Oct 29 •

Six Month Pause on Research Applications at California's Stem Cell and Gene Therapy Program

Multibillion-dollar enterprise needs time to work through its sweeping, new priorities

Oct 4 •

'All Not Well in Gene Therapy World' -- Denial of Coverage, Delays and Complications

Implications for $12 billion California program and its mandate for affordability

Sep 17 •

California Plan to Maximize Impact of $3.9 Billion for Stem Cell/Gene Therapies Clears Critical Hurdle

Major goals? Fifteen to 20 new, late stage clinical trials, six to 10 rare disease treatments ready for commercialization

Sep 13 •

Rare Diseases Receive Preliminary Research Boost From California's Gene Therapy/Stem Cell Agency

$3.9 billion worth of new priorities under review, only one more public session before full CIRM board action

Aug 19 •

Want to Help Plan the Financial Future of a Multibillion-Dollar, Biomedical, California Research Enterprise?

The job involves 'CIRM's lifespan' along with audits and accounting.

Aug 15 •

Text from UCLA Researcher Donald Kohn on his Bubble Baby Clinical Trial

Status report and treatment of five-year-old Jakob included

Jul 27 •

Dr. Moustache and the Bubble Baby Disease: A CIRM Success Story

More than 50 patients treated successfully, but a commercialization caveat

Jul 27 •

Trail Guide to $3.9 Billion in Looming Changes at California's Stem Cell and Gene Therapy Program

Who wins, who loses? The priority review is laying the groundwork for decisions about dollars.

Jul 25 •

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts